Welcome to our dedicated page for Spyre Therapeutics SEC filings (Ticker: SYRE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Spyre Therapeutics, Inc. (SYRE) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Spyre is a clinical-stage biotechnology company listed on the Nasdaq Global Select Market, and its filings document material events, financing activities, and key clinical development updates related to its long-acting antibody programs for inflammatory bowel disease and rheumatic diseases.
Recent Form 8-K reports describe, for example, interim Phase 1 results for SPY003, an investigational extended half-life antibody targeting the p19 subunit of IL-23, including safety and pharmacokinetic findings that the company states support potential quarterly or twice-yearly maintenance dosing. Other 8-K filings detail the initiation and structure of the SKYLINE Phase 2 platform trial in ulcerative colitis and the SKYWAY Phase 2 basket trial in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis, as well as financial results and preliminary cash balances for specific quarters.
Spyre’s filings also include disclosures about public equity offerings under its shelf registration statement on Form S-3. An 8-K dated October 15, 2025, for example, outlines the terms of an underwritten public offering of common stock, gross proceeds, and the company’s stated intention to use net proceeds to advance programs in IBD and rheumatic diseases, support preclinical and clinical work, manufacturing, and Phase 3 readiness activities, and provide working capital.
On Stock Titan, users can review these filings in sequence and use AI-powered tools to summarize lengthy documents, highlight key sections, and quickly identify items related to clinical data, financing, and other material events disclosed by Spyre Therapeutics.
SPYRE THERAPEUTICS, INC. Schedule 13G: Perceptive Advisors, Joseph Edelman and Perceptive Life Sciences Master Fund report beneficial ownership of 4,319,496 shares of Common Stock, representing 5.0% of the class. The filing states the outstanding share count as 85,664,811 shares as reported in a prospectus supplement filed April 16, 2026. Perceptive Life Sciences Master Fund directly holds the shares; Perceptive Advisors and Mr. Edelman disclose shared voting and dispositive power as investment manager and managing member, respectively.
Spyre Therapeutics' major shareholders have reaffirmed their stakes and agreed to a short-term lock-up. Fairmount Funds Management LLC and Fairmount Healthcare Fund II L.P. report beneficial ownership of 8,184,941 shares, or 9.09% of Spyre’s common stock, including common shares and Series A preferred stock on an as-converted basis, subject to a 9.99% beneficial ownership limitation. Individuals Peter Harwin and Tomas Kiselak each report beneficial ownership of 9,016,702 shares, or 9.99% of the class, combining direct holdings, options exercisable within 60 days, and Fund II’s preferred and common shares. The amendment notes that these ownership levels are unchanged from the prior amendment and is filed primarily to disclose that the reporting persons entered into a 60-day lock-up agreement in connection with the company’s underwritten public offering, during which they have agreed not to sell Spyre securities without underwriter consent.
Spyre Therapeutics, Inc. entered an underwriting agreement for a public offering of 6,500,000 shares of common stock at $62.00 per share, plus a 30‑day option for 975,000 additional shares that the underwriters fully exercised. The offering, made off an effective Form S-3 shelf, closed with gross proceeds of about $463.5 million before fees and expenses. Spyre plans to use the net proceeds to advance its inflammatory bowel disease and rheumatic disease programs, including preclinical work, clinical trials, manufacturing and Phase 3 readiness for its antibody programs, and for working capital and general corporate purposes.
Spyre Therapeutics, Inc. is offering 6,500,000 shares of its common stock at a public offering price of $62.00 per share, representing a total public offering price of $403,000,000. The company expects to receive approximately $378.8M in proceeds before expenses and has granted the underwriters a 30-day option to purchase up to 975,000 additional shares. The underwriters expect to deliver the shares on or about April 16, 2026. The prospectus supplement states the company had approximately $741M of cash, cash equivalents and marketable securities as of March 31, 2026, and that net proceeds will fund its IBD and rheumatic disease antibody programs, development activities, manufacturing and general corporate purposes.
Spyre Therapeutics, Inc. is proposing a primary offering of $300,000,000 of common stock on the Nasdaq Global Select Market (symbol SYRE), with underwriters holding a 30-day option to purchase additional shares. The prospectus states a last reported sale price of $51.29 per share on April 10, 2026.
The company reported positive 12-week SKYLINE Part A induction topline results for SPY001 (change in RHI: -9.2, p<0.0001), said Part A recruitment is closed and Part B enrollment is open, and expects further readouts mid-2026 and in 2027. Spyre also reported approximately $741 million of cash, cash equivalents and marketable securities as of March 31, 2026 (preliminary).
Spyre Therapeutics, Inc. is proposing a primary offering of $300,000,000 of common stock on the Nasdaq Global Select Market (symbol SYRE), with underwriters holding a 30-day option to purchase additional shares. The prospectus states a last reported sale price of $51.29 per share on April 10, 2026.
The company reported positive 12-week SKYLINE Part A induction topline results for SPY001 (change in RHI: -9.2, p<0.0001), said Part A recruitment is closed and Part B enrollment is open, and expects further readouts mid-2026 and in 2027. Spyre also reported approximately $741 million of cash, cash equivalents and marketable securities as of March 31, 2026 (preliminary).
Spyre Therapeutics, Inc. reported preliminary cash, cash equivalents and marketable securities of approximately $741 million as of March 31, 2026, including $30 million of legacy asset disposition proceeds. About $23 million of these proceeds is expected to be paid to contingent value rights holders in the second quarter of 2026.
These figures are unaudited, subject to closing procedures and may change. Effective April 13, 2026, the company suspended and terminated its at-the-market offering prospectus under its Sales Agreement with TD Securities (USA) LLC, so no further ATM sales will occur unless a new prospectus or registration statement is filed.
Spyre Therapeutics, Inc. reported preliminary cash, cash equivalents and marketable securities of approximately $741 million as of March 31, 2026, including $30 million of legacy asset disposition proceeds. About $23 million of these proceeds is expected to be paid to contingent value rights holders in the second quarter of 2026.
These figures are unaudited, subject to closing procedures and may change. Effective April 13, 2026, the company suspended and terminated its at-the-market offering prospectus under its Sales Agreement with TD Securities (USA) LLC, so no further ATM sales will occur unless a new prospectus or registration statement is filed.
Spyre Therapeutics reported positive 12-week induction results from Part A of its Phase 2 SKYLINE trial of SPY001 in moderate-to-severely active ulcerative colitis. SPY001 met the primary endpoint with a statistically significant 9.2-point reduction in Robarts Histopathology Index (p<0.0001).
Key secondary endpoints were also encouraging, with clinical remission by modified Mayo Score in 40% of patients and endoscopic improvement in 51%. Among 43 treated patients, 14% experienced treatment-emergent adverse events and one serious event, which investigators deemed not drug-related, supporting a safety profile consistent with the α4β7 class. Part A recruitment is closed and Part B, including monotherapy and combination cohorts, is now enrolling with additional readouts expected in 2026 and 2027.
Spyre Therapeutics reported positive 12-week induction results from Part A of its Phase 2 SKYLINE trial of SPY001 in moderate-to-severely active ulcerative colitis. SPY001 met the primary endpoint with a statistically significant 9.2-point reduction in Robarts Histopathology Index (p<0.0001).
Key secondary endpoints were also encouraging, with clinical remission by modified Mayo Score in 40% of patients and endoscopic improvement in 51%. Among 43 treated patients, 14% experienced treatment-emergent adverse events and one serious event, which investigators deemed not drug-related, supporting a safety profile consistent with the α4β7 class. Part A recruitment is closed and Part B, including monotherapy and combination cohorts, is now enrolling with additional readouts expected in 2026 and 2027.
Spyre Therapeutics, Inc. is holding its 2026 virtual annual stockholder meeting on May 27, 2026 to vote on four key items. Stockholders will elect three Class I directors, cast an advisory “say-on-pay” vote on executive compensation, ratify KPMG LLP as auditor, and approve an amended and restated 2016 Employee Stock Purchase Plan reserving 1,056,096 shares. The company highlights its classified board, supermajority voting and other governance practices, and notes 78,784,358 common shares outstanding as of April 2, 2026.
Spyre Therapeutics, Inc. Chief Executive Officer Turtle Cameron reported open-market sales of company stock. On April 1, 2026, he sold a total of 15,000 shares of common stock in two transactions, at weighted average prices of $49.20 and $49.92 per share.
The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 20, 2025. After these transactions, Cameron directly holds 627,540 shares of Spyre Therapeutics common stock, including 116,168 shares that vest in monthly installments through November 2026, contingent on his continued service.